A Monocentric Retrospective Study about the Correlation between Histology and Cytology of Thyroid Indeterminate Nodules Classified as TIR 3A and TIR 3B, according to 2014 Italian Consensus for Classification and Reporting of Thyroid Cytology

الملخص EN

Background.

In 2014, the Italian Consensus for Classification and Reporting of Thyroid Cytology (ICCRTC) reviewed the previous cytological classification proposed in 2007 including the subdivision of TIR 3 category into low risk (TIR 3A) and high risk (TIR 3B).

In Italian literature, different rates of malignancy have been correlated to these subcategories.

Objectives.

The aim of the study is to present our experience on this subclassification for the assessment of the malignancy risk of indeterminate thyroid nodules.

We correlated the subdivision into TIR 3A and TIR 3B with the histological report by highlighting the rates of malignancy detected in the two subcategories.

On the one hand, we aimed to check if the groups are associated with a real and significant difference risk of malignancy.

On the other hand, we evaluated the use of this subdivision in the choice of the appropriate treatment.

Study Design.

This is a retrospective review of all the patients with an indeterminate nodule who underwent US-FNA and had surgery at ASL Città di Torino between January 2005 and May 2018.

Results.

150 patients have been analyzed for the research; 62 (41.3%) had a malignant histological report.

Rates of malignancy between TIR 3A (20.8%) and TIR 3B (60.3%) were significantly different (p<0.0001).

The subclassification had high sensitivity (75.8%; CI 63.3–85.8%) and NPV (79.3%; CI 68–87.8%) and low specificity (64.8%; CI 53.9–74.7%) and PPV (60.3; CI 48.5–71.2%).

The measurement of the accuracy (AUC = 0.7) classified the test as “moderately accurate.” Conclusions.

Obtained data show a great rate of false negative (20.8%) and limited AUC (0.7).

According to our logistic regression, we argue that the 2014 subclassification into TIR 3A and TIR 3B should be considered for the choice of patient treatment, but at the same time, we believe that the association with other screening tests is necessary to increase the accuracy in the future.